On September 29, 2026, Invivyd announced positive topline results from the Phase 3 LIBERTY study for its investigational monoclonal antibody VYD2311. The study demonstrated that VYD2311 has a safety and tolerability profile statistically superior to an mRNA-based COVID-19 vaccine, with significantly lower rates of treatment-emergent adverse events (56.5% vs 91.4%) over six days. Co-administration of VYD2311 with the mRNA vaccine did not interfere with neutralizing titers and increased them by approximately 2.5x. Invivyd plans to submit a Biologics License Application to the FDA via the Accelerated Approval Program, relying on LIBERTY data and upcoming safety/immunogenicity results from the pivotal DECLARATION study expected in October 2026. Invivyd is a biopharmaceutical company developing monoclonal antibodies for viral infectious diseases.
